Krystal Biotech (KRYS) Share-based Compensation (2016 - 2026)

Krystal Biotech has disclosed Share-based Compensation across 11 years of filings, most recently posting $13.6 million for Q1 2026.

• Share-based Compensation for Q1 2026 came in at $13.6 million, up 0.97% year-over-year; the trailing twelve-month figure through Mar 2026 was $54.6 million (up 2.51% YoY), and the FY2025 annual result was $54.5 million, up 10.97% from the prior year.
• Share-based Compensation came in at $13.6 million for Q1 2026 at Krystal Biotech, down from $13.8 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $14.1 million in Q2 2025 to a low of $6.4 million in Q1 2022.
• The 5-year median for Share-based Compensation is $11.3 million (2023), against an average of $11.2 million.
• Across the five-year window, Share-based Compensation surged 177.99% in 2022 and declined 10.9% in 2024, its largest moves.
• Krystal Biotech's Share-based Compensation stood at $9.6 million in 2022, then climbed by 3.15% to $9.9 million in 2023, then jumped by 35.55% to $13.4 million in 2024, then climbed by 3.05% to $13.8 million in 2025, then retreated by 1.13% to $13.6 million in 2026.
• The last three Share-based Compensation figures came in at $13.6 million (Q1 2026), $13.8 million (Q4 2025), and $13.2 million (Q3 2025), per Business Quant data.